The Gulf Journal of Dermatology and Venereology ABSTRACT Psoriasis vulgaris and bullous pemphigoid represent two clinically well-characterized, chronic, inflammatory skin diseases. The concomitant occurrence of these two entities in a patient is rare, and the exact nature of this relationship is not clear. We describe a 31-year-old woman with a history of plaque-type psoriasis who presented wit...

The psoriasis-associated antigen, pso p27, can be isolated from psoriasis scale and is present in complement-activating immune complexes in psoriatic scale, and in serum from patients with psoriasis. The antigen is produced by tryptase-positive cells in the skin lesions and is shown to be a major antigen in the immune reactions in psoriasis. The synthesis of this particular antigen is reduced w...

Background: Non-pustular annular psoriasis is a rare condition in which type of plaque appears with ring-like lesions and clearer central appearance. The disease activities may be evaluated clinically. It essential to provide more meaningful approach treatment management.

The aim of this study was to evaluate the relationship between itch and the well-being of patients with psoriasis. In a study of 102 patients with plaque-type psoriasis, pruritus was found in 91 (89.2%) patients during exacerbation of psoriasis. No significant correlation was found between disease severity and the presence and intensity of pruritus. However, pruritus intensity correlated signif...

The authors conducted a prospective, open-label, pilot trial of the effects of the antidiabetic thiazolidinedione (TZD) rosiglitazone in two patients with moderate to severe plaque psoriasis. Case 1: A lean, euglycemic 43-year-old nondiabetic man with a 2-year history of plaque psoriasis presented with lesions involving 10% of his body surface (Figures 1A, 1B, 1C). He had no other chronic or ac...

Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients moderate-to-severe plaque psoriasis have not been extensively examined.

Previous studies have suggested a benefit for patients with plaque psoriasis when omega-3 fatty acids are added to topical treatment. This study evaluated the efficacy of a nutritional complement rich in omega-3 fatty acids in patients with mild or moderate plaque psoriasis. Thirty patients were recruited, 15 of whom were given topical treatment with tacalcitol, forming the control group. The r...

Psoriasis is a chronic inflammatory skin disease affecting about 1-3% of the general population. Moderate-to-severe psoriasis is commonly associated with various comorbidities, including psoriatic arthritis (PsA) and cardio-metabolic disorders such as obesity, hypertension, diabetes, and metabolic syndrome. There is increasing recognition that systemic inflammation accompanies severe skin disea...